Abstract:We previously observed that purified recombinant glucocorticoid receptor (GR) protein specifically binds to the D-sequence within the inverted terminal repeat of the AAV2 genome because the D-sequence shares partial homology to the consensus half-site of the glucocorticoid receptor-binding element (GRE). The half-site is an essential core element, which has been reported to be sufficient to mediate GR signaling. Substitution of the D-sequence with the authentic GRE further increased AAV2 vector-mediated transgene expression. Based on these observations, we systemically examined whether AAV2 infection involves the GR signaling pathway. Our results showed that following infection by wild-type (WT) AAV2, or transduction with recombinant AAV2 vectors in vitro, GR was activated. The serine phosphorylated form of GR in whole cell lysates was significantly increased in a dose-dependent manner 18 hours post viral infection/vector transduction. Translocation and accumulation of GR in the nucleus was also increased correspondingly. To further corroborate our findings in an in vivo model, C57BL/6 mice were injected via tail-vein with either WT-AAV2 (1×1012 vgs/mouse) or AAV2-EGFP vectors (5×1011 vgs/mouse) and sacrificed 16 hours post virus/vector administration. A significant increase in the serine phosphorylated form of GR was also observed in liver tissues. We also observed that in cell cultures, dexamethasone, a well-known activator of GR, significantly enhanced rAAV2 vector-mediated transgene expression in various GR-positive cell lines, but not in a GR-deficient human osteosarcoma cell line, U2OS. Furthermore, stable transfection of U2OS cells with a GR expression plasmid not only facilitated AAV2 vector transduction, but also restored the ability of dexamethasone to further increase AAV2 vector-mediated transgene expression. Together with our previous data, we propose a model for elucidating the role of glucocorticoid receptor signaling pathway in AAV2 infection/AAV2 vector transduction (Fig. 1). Upon viral transduction or stimulation with glucocorticoids, the cytoplasmic GR is phosphorylated and translocated into the nucleus. Following AAV2 entry into the nucleus, the viral genome is released. Upon viral second-strand DNA synthesis or annealing of the complementary DNA strands, the activated GR binds to the double-stranded D-sequence in the viral inverted terminal repeats and consequently, enhances transgene expression. The activated GR also regulates its downstream pathways, such as NF-kB, which we have previously shown to have a substantial effect on AAV2 vector-mediated transgene expression (Proc Natl Acad Sci USA, 108:3743-3738, 2011). A better understanding of the complex interaction between GR and NF-kB signaling pathways notwithstanding, the availability of the fully functional GRE site-substituted novel AAV vectors to achieve high-efficiency transgene expression has implications in the potential use of these vectors in human gene therapy.

Enhanced transgene expression from single-stranded AAV vectors in human cells in vitro and in murine hepatocytes in vivo

310. Development of Generation X Recombinant AAV Vectors for Human Gene Therapy

11. the Role of Glucocorticoid Receptor Signaling in Adeno-Associated Virus 2 Infection

Enhanced Transgene Expression from Recombinant Single-Stranded D-sequence-substituted Adeno-Associated Virus Vectors in Human Cell Lines in Vitro and in Murine Hepatocytes in Vivo.

High-efficiency transduction of primary human hematopoietic stem cells and erythroid lineage-restricted expression by optimized AAV6 serotype vectors in vitro and in a murine xenograft model in vivo.

99. A Novel Mechanism of Transduction of Human Cells by Recombinant AAV Vectors

313. Development of the AAV6-Based Vectors with Selective Tropism and High Transduction Efficiency of Human Cancer Cells

315. Optimization of the Capsid of Recombinant Adeno-Associated Virus 6 (AAV6) Vectors for Liver-, and Muscle-Directed Gene Therapy

AAV2 vector optimization for retinal ganglion cell-targeted delivery of therapeutic genes

550. Primary Human CD34+ Hematopoietic Stem/Progenitor Cell (HSPC) Transduction by AAV6 Serotype Vectors: Strategies for Overcoming the Donor-Variation

91. Development of Optimized [“opt”] AAV Vectors by Combining Capsid-Modified NextGen and Genome-Modified GenX AAV Vectors for High-Efficiency Transduction at Further Reduced Doses

Enhanced Transduction of Human Hematopoietic Stem Cells by AAV6 Vectors: Implications in Gene Therapy and Genome Editing

10. High-Efficiency Transduction of Primary Human CD34+ Hematopoietic Stem/Progenitor Cells by AAV6 Serotype Vectors: Strategies for Overcoming Donor Variation and Implications in Genome Editing

Substantially improved gene transfer to interneurons with second-generation glutamate receptor-targeted DART-AAV vectors

Optimizing the Transduction Efficiency of Capsid-Modified Aav6 Serotype Vectors in Primary Human Hematopoietic Stem Cells in Vitro and in A Xenograft Mouse Model in Vivo

Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors.

Development of Optimized Aav Serotype Vectors for High-Efficiency Transduction at Further Reduced Doses

Development of Novel AAV Serotype 6 Based Vectors with Selective Tropism for Human Cancer Cells

High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy.

Optimization of the Capsid of Recombinant Adeno-Associated Virus 2 (AAV2) Vectors: the Final Threshold?

RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism.